(Reuters) – The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s therapy for treating a type of multiple myeloma, giving another treatment option to patients with the incurable blood cancer, the regulator said on Tuesday.
(Reporting by Raghav Mahobe, Manas Mishra, Khushi Mandowara and Amruta Khandekar in Bengaluru; Editing by Anil D’Silva)
